- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Early Automated Insulin Delivery Improves Outcomes in Type 1 Diabetes: Study

A study published in the journal of Diabetes Technology & Therapeutics found that children with type 1 diabetes who began using automated insulin delivery (AID) systems within six months of diagnosis achieved better long-term glycemic control and experienced fewer episodes of diabetic ketoacidosis over a 2-year period when compared to nonusers. Researchers suggest that early adoption of these systems may help blunt the typical rise in A1C levels seen after the honeymoon phase of diabetes, according to Dr. Elizabeth Mann.
Automated insulin delivery systems combine continuous glucose monitoring with insulin pumps that automatically adjust insulin delivery based on real-time blood sugar readings. The systems are considered as a major advancement in diabetes care, especially for children and adolescents who often face significant challenges maintaining stable glucose levels.
This retrospective cohort study analyzed data from 9,856 young people diagnosed with type 1 diabetes between 2020 and 2022 across 27 diabetes centers in the US. This study examined how the timing of AID initiation influenced hemoglobin A1c (HbA1c) levels, diabetic ketoacidosis (DKA), and severe hypoglycemia during the first two years after diagnosis.
These participants were divided into four groups based on when they began using AID technology: within six months of diagnosis, between six and 12 months, between 13 and 24 months, or no AID use at all. The children who began using AID systems within the first six months after diagnosis had a median HbA1c level of 7.1% at 24 months, which was considered close to recommended treatment targets.
By comparison, participants who never used AID technology had substantially poorer glucose control, with median HbA1c levels reaching 9.8% after two years. The timing of AID initiation remained an independent predictor of HbA1c outcomes even after adjusting for other clinical and demographic variables, which suggested that earlier adoption itself contributes meaningfully to improved diabetes management.
DKA occurred approximately three times more often among children who did not use AID systems when compared to those who started early. These findings reinforce growing evidence that rapid integration of diabetes technology shortly after diagnosis may improve both short-term safety and long-term metabolic control.
The early period after type 1 diabetes diagnosis can be especially challenging for families as they learn insulin dosing, carbohydrate counting, glucose monitoring, and emergency management. Overall, the findings emphasized that timely initiation of AID systems may depend on insurance coverage, healthcare resources, socioeconomic factors, and disparities in technology availability.
Source:
Mann, E. A., Prahalad, P., Wolf, R., Mathioudakis, N., Rioles, N., Rompicherla, S., Odugbesan, O., Thapa, S., Vigersky, R., & Ebekozien, O. (2026). Early initiation of automated insulin delivery at type 1 diabetes diagnosis in children and adolescents is associated with improved outcomes. Diabetes Technology & Therapeutics, 15209156261441491, 15209156261441491. https://doi.org/10.1177/15209156261441491
Dr Kartikeya Kohli is an Internal Medicine Consultant at Sitaram Bhartia Hospital in Delhi with super speciality training in Nephrology. He has worked with various eminent hospitals like Indraprastha Apollo Hospital, Sir Gangaram Hospital. He holds an MBBS from Kasturba Medical College Manipal, DNB Internal Medicine, Post Graduate Diploma in Clinical Research and Business Development, Fellow DNB Nephrology, MRCP and ECFMG Certification. He has been closely associated with India Medical Association South Delhi Branch and Delhi Medical Association and has been organising continuing medical education programs on their behalf from time to time. Further he has been contributing medical articles for their newsletters as well. He is also associated with electronic media and TV for conduction and presentation of health programs. He has been associated with Medical Dialogues for last 3 years and contributing articles on regular basis.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

